Table 7.
Proportions of patients receiving OROS-MPH <1 DDD, 1–2 DDDs, and ≥2 DDDs during the study period (cross-sectional dataset)
| <1 DDD | 1–2 DDDs | ≥2 DDDs | |
|---|---|---|---|
| N (%) of adults with diagnosed ADHD who reported use of OROS-MPH treatmenta | 5,476 (25.0) | 9,951 (45.4) | 6,499 (29.6) |
| Malesb | 2,716 (49.6) | 5,326 (53.5) | 3,983 (61.3) |
| Femalesb | 2,760 (50.4) | 4,625 (46.5) | 2,516 (38.7) |
| Age group, n (%)a | |||
| 18–21 years | 1,470 (29.7) | 2,587 (52.3) | 885 (17.9) |
| 22–64 years | 3,992 (23.6) | 7,339 (43.3) | 5,599 (33.1) |
| ≥65 years | 14 (26.0) | 25 (46.3) | 15 (27.8) |
Notes: 1 DDD31 =30 mg MPH.
a
Denominators for percentages in this row are the total number of patients included in the row.
b
Denominators for percentages in this row are the total number of patients per DDD group (<1 DDD, 1–2 DDDs, ≥2 DDDs).
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DDD, defined daily dose; OROS-MPH, osmotic release oral system methylphenidate.